- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | PROKIDNEY CORP. - 8-K, Current Report | 1 | SEC Filings | ||
| 26.12.24 | ProKidney (NASDAQ:PROK) Shares Down 2.5% - What's Next? | 2 | MarketBeat | ||
| 07.12.24 | ProKidney (NASDAQ:PROK) Trading 8.4% Higher - What's Next? | 5 | MarketBeat | ||
| 22.11.24 | PROKIDNEY CORP. - 8-K, Current Report | - | SEC Filings | ||
| 12.11.24 | ProKidney GAAP EPS of -$0.14 | 2 | Seeking Alpha | ||
| 12.11.24 | ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting | 112 | GlobeNewswire (Europe) | FDA confirmed in a recent FDA Type B meeting under RMAT designation that the PROACT 1 Phase 3 study could be sufficient to support a full U.S. regulatory approval of rilparencelFDA also confirmed... ► Artikel lesen | |
| 14.10.24 | ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 | 1 | GlobeNewswire (USA) | ||
| 09.10.24 | ProKidney to Participate in the UBS Virtual Organ Restoration Day | 2 | GlobeNewswire (USA) | ||
| PROKIDNEY Aktie jetzt für 0€ handeln | |||||
| 30.09.24 | JPMorgan beginnt Aktienanalyse von ProKidney mit neutraler Bewertung | 2 | Investing.com Deutsch | ||
| 30.09.24 | JPMorgan starts ProKidney stock coverage with Neutral rating | 3 | Investing.com | ||
| 20.09.24 | ProKidney executive sells $41,030 in company stock | 1 | Investing.com | ||
| 10.09.24 | Guggenheim highlights ProKidney stock upside in addressing unmet needs for CKD patients | 2 | Investing.com | ||
| 09.08.24 | ProKidney Reports Business Updates and Second Quarter 2024 Financial Results | 239 | GlobeNewswire (Europe) | Reported interim REGEN-007 data that demonstrate rilparencel's potential to preserve kidney function in patients with diabetes and advanced CKDRestarted manufacturing and resumed PROACT 1 and PROACT... ► Artikel lesen | |
| 10.06.24 | ProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational Updates | 156 | GlobeNewswire (Europe) | Interim results of REGEN-007 Phase 2 trial show stabilization of kidney function for 18 monthsSafety profile consistent with prior studies and comparable to kidney biopsyResumed manufacturing and... ► Artikel lesen | |
| 10.05.24 | ProKidney Reports Business Updates and First Quarter 2024 Financial Results | 311 | GlobeNewswire (Europe) | Final results from RMCL-002 Phase 2 trial to be presented in the Late Breaking Clinical Trials session at the European Renal Association (ERA) Congress on May 25, 2024. An investor call to provide... ► Artikel lesen | |
| 25.03.24 | ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations | 167 | GlobeNewswire (Europe) | Dr. Ulrich Ernst joins as Executive Vice President of Technical Operations with a deep background and expertise in process development and manufacturing of cell therapies Mr. Lucio Tozzi joined in... ► Artikel lesen | |
| 22.03.24 | ProKidney Reports Full Year 2023 Financial Results and Recent Corporate Highlights | 150 | GlobeNewswire (Europe) | WINSTON-SALEM, N.C., March 21, 2024 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) ("ProKidney" or the "Company"), a leading late clinical-stage cellular therapeutics company focused on chronic... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ORGANOVO | 0,688 | +12,97 % | Organovo, Inc.: Organovo's FXR Program, including FXR314, to Be Acquired by Eli Lilly and Company | SAN DIEGO, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO) ("Organovo" or the "Company"), a clinical stage biotechnology company focused on developing novel treatment approaches... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,800 | -5,76 % | INOVIO Pharmaceuticals, Inc.: Clinical and Immunological Results from Phase 1/2 Study of INO-3107 as a Treatment for Recurrent Respiratory Papillomatosis Published in Nature Communications | Data shows that INO-3107 induced new populations of T cells in the blood that traveled to airway tissue and were associated with clinical benefit as measured by... ► Artikel lesen | |
| GENMAB | 213,10 | -2,29 % | Genmab A/S - admittance to trading and official listing of new shares due to employee warrant exercise | The share capital of Genmab A/S has been increased. The admittance to trading and official listing will take effect as per 28 February 2025 in the ISIN below.
ISIN:
DK0010272202
Name:
Genmab
Volume... ► Artikel lesen | |
| LEAP THERAPEUTICS | 0,440 | -1,35 % | Leap Therapeutics, Inc.: Leap Therapeutics Reports Initial Clinical Data from Part B of the DeFianCe Study and Part C of the DisTinGuish Study | 35% objective response rate (ORR) in second-line colorectal cancer (CRC) patients treated with sirexatamab (DKN-01) plus bevacizumab and chemotherapy, compared to... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 2,610 | 0,00 % | Pre-market Movers: Enveric Biosciences, Interactive Strength, Flywire, Grocery Outlet Holding, National Vision Holdings | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.50 A.M. ET).In the Green Enveric Biosciences, Inc. (ENVB) is up over 155%... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 0,637 | +2,49 % | Verrica Pharmaceuticals Inc.: Verrica Provides Business and Operational Update | -- Dispensed applicator units in the fourth quarter of 2024 have exceeded the complete prior quarter even with significant cost reductions in sales and operational infrastructure -- Observed significant... ► Artikel lesen | |
| RELMADA THERAPEUTICS | 0,246 | -3,91 % | Relmada Therapeutics Aktie: Auf einer Gratwanderung | Das Biotechnologie-Unternehmen Relmada Therapeutics steht vor einem bedeutenden Wendepunkt in seiner Unternehmensgeschichte. Nach einer umfassenden Bewertung durch das Datenüberwachungskomitee hat sich... ► Artikel lesen | |
| BIOATLA | 0,307 | 0,00 % | BioAtla, Inc.: BioAtla and Context Therapeutics Announce Exclusive Worldwide License Agreement to Develop and Commercialize BA3362, a Nectin-4 x CD3 T Cell Engaging Antibody | Context to obtain exclusive development and commercialization rights to BA3362 BioAtla to receive $15.0 million in upfront and near-term milestones, and further potential clinical, regulatory and... ► Artikel lesen | |
| REPARE THERAPEUTICS | 1,175 | 0,00 % | Repare Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| THERANEXUS | 0,473 | -1,46 % | THERANEXUS PUBLISHES ITS CASH POSITION AS OF 31 DECEMBER 2024 AND PRESENTS ITS PROGRESS REPORT | Lyon, France - 30 January 2025, 6pm CET - Theranexus, a biopharmaceutical company innovating in the treatment of rare neurological diseases, today announces publication of its cash position as... ► Artikel lesen | |
| BOUNDLESS BIO | 1,745 | -9,11 % | Boundless Bio, Inc.: Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer | SAN DIEGO, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies... ► Artikel lesen | |
| TRANSCODE THERAPEUTICS | 1,900 | 0,00 % | TransCode Therapeutics, Inc. Announces Results of Special Meeting | BOSTON, Feb. 25, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) ("TransCode" or the "Company"), the RNA Oncology Company committed to more... ► Artikel lesen | |
| PEPGEN | 2,820 | 0,00 % | PepGen Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | BOSTON--(BUSINESS WIRE)--PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment... ► Artikel lesen | |
| QIAGEN | 36,890 | +0,16 % | Qiagen NV-Aktie kann Vortagsniveau nicht halten (37,31 €) | Im Minus liegt zur Stunde die Aktie von Qiagen NV . Der jüngste Kurs betrug 37,31 Euro. Für das Wertpapier von Qiagen NV steht gegenwärtig ein Verlust von 1,39 Prozent zu Buche. Die Aktie verbilligte... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,590 | 0,00 % | Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous... ► Artikel lesen |
PROKIDNEY CORP gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,100 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PROKIDNEY CORP finden Sie auf Wallstreet Online.
